BRAF and metastatic melanoma: A total of six RCTs investigating BRAF inhibitors for previously untreated metastatic melanoma reported overall survival results and were included in this study: dabrafenib was investigated in trials BREAK-3 [35, 36] and COMBI-d [13, 37]; trametinib was investigated in trial METRIC [34]; vemurafenib was investigated in trials BRIM3 [26, 28], COMBI-v [12], and co-BRIM [38]; and dabrafenib + trametinib was investigated in trials COMBI-d [13, 37] and COMBI-v [12].